




版權說明:本文檔由用戶提供并上傳,收益歸屬內容提供方,若內容存在侵權,請進行舉報或認領
文檔簡介
1、Chapter 38Macrolides, Lincomycins and Polymycins大環內酯類藥物大環內酯類藥物v14元大環內酯類元大環內酯類:紅霉素、羅紅霉素、克拉霉素、地紅霉素v15元大環內酯類元大環內酯類:阿奇霉素v16元大環內酯類元大環內酯類:螺旋霉素、乙酰螺旋霉素、麥迪霉素、麥白霉素、羅他霉素、柱晶白霉素、交沙霉素、米歐卡霉素Macrolides vFirst generation : 1950serythromycinvSecond generation:1970sclaithromycin azithromycinvThird generation:Common pr
2、operties of MacrolidesAntibacterial activityvFirst generationMost G+ organisms: pneumococci, streptococci, staphylococci , diphtheriae etcPart G- organisms:legionella(軍團菌)(軍團菌),bacillus pertussis(百日咳百日咳), brucella(布氏布氏) etcOthers: mycoplasma(支原體支原體), chlamydia trachomatis(沙眼衣原體沙眼衣原體), rickettsia(立克次
3、體立克次體), spirochete ,anaerobes etc. vSecond generationMore active on G- organismsMechanism of actionvTarget 50s ribosomal RNAvMechanism inhibition of translocation of mRNAMechanism of resistancevProduction of inactivating enzymesvModification of the ribosomal binding sitevActive efflux systemvMLSRPha
4、rmokinetics vAbsorptionErythromycin: not stable at acid pHNew macrolides: stable povDistribution vMetabolism: Erythromycin&clarithromycin: in livervExcretion Erythromycin& azithromycin: bileClarithromycin: kidneyCommomly used macrolidesErythromycin vAntimicrobial activityGram-positive organisms: pne
5、umococci, streptococci, staphylococci , diphtheriae etcGram-negative organisms:legionella(軍團(軍團菌)菌),bacillus pertussis(百日咳百日咳), brucella(布氏布氏) , meningococci, diplococcus gonorrhoeae etcOthers: mycoplasma(支原體支原體), chlamydia trachomatis(沙眼衣原體沙眼衣原體), rickettsia(立克次體立克次體), spirochete ,anaerobes etc. Er
6、ythromycinvClinical uses vAs penicillin substitute in penicillin-allergic or resistant patients with infections caused by staphylococci, streptococci and pneumococcivPertussis,diphtheriaevLegionella and mycoplasma pneumoniavH.p infectionErythromycinvAdverse reactionsGastrointestinal effectsLiver tox
7、icityCardiotoxicity Erythromycin vErythromycin lactobionate(乳糖酸紅霉素)乳糖酸紅霉素)verythromycin estolate(無味紅霉素(無味紅霉素)verythromycin stearate(硬脂酸紅霉素)硬脂酸紅霉素)verythromycin ethylsuccinate(琥乙紅霉素,(琥乙紅霉素, 利君沙利君沙) New macrolides antibioticsvAdvantage :Broader spectrum, higher activityOrally effectiveHigh blood conce
8、ntrationLonger t 1/2Less toxicityMainly used in respiratory tract infectionClarithromycin(甲紅霉素(甲紅霉素,克拉霉素)克拉霉素)vHas the strongest activity on Gram-positive bacteria, legionella pneumophila, chlamydia pneumoniae and H.pvGood pharmacokinetic propertyvLow toxicityAzithromycin (阿齊霉素阿齊霉素,麗珠奇樂)麗珠奇樂)vHas th
9、e strongest activity against mycoplasma pneumoniae(肺炎支原體)(肺炎支原體)vMore effective on Gram-negative bacteriavWell toleratedvT1/2 :3548h once dailyvMainly used in respitory tract infectionRoxithromycin (羅紅霉素,嚴迪)(羅紅霉素,嚴迪) v1987 FrancevThe highest blood concentration vF 72%85%vRespiratory tract infection
10、and soft tissue infectionvLow adverse effectsLincomycin and ClindamycinvAntimicrobial activityGram-positive organismsBacteroide fragilis and other anaerobesvMechanism Binding to 50s ribosome subunit and inhibiting protein synthesisvPharmacokineticsAbsorbed wellPenetrate well into most tissues includ
11、ing bone ClindaycinvClinical uses Severe anaerobic infection Acute or chronical suppurative osteomylitis , arthritis caused by susceptive organisms especially Staphylococci aureusvAdverse reactionsGastrointestinal effects: severe diarrhea and pseudomembranous enterocolitis caused by Clostridium diff
12、icile :vancomycin & metronidazoleOther :Impaired liver function , neutropeniaPolypeptide antibioticsvVancomycin & TeicoplaninvPolymyxinsvbactitracinVancomycin vMechanism of actionInhibit cell wall synthesisvAntimicrobial spectrum:Narrow spectrum, active only against gram-positive bacteria paticularl
13、y staphylococcivPharmacokineticsPoorly absorbed from intestinal tract, ivExcreted from glomerular filtration 90%VancomycinvClinical uses Infection caused by MRSA, MRSE and penicillin-resistant pneumococcusTreatment of antibiotic-associated enterocolitis caused by clostridium difficile povAdverse rea
14、ctionOtotoxicity & nephrotoxicityRed-man syndromeTeicoplanin vSimilar to vancomycin in mechanism and antimicrobial spectrumvCan be given im as well as ivvLess adverse reactionsPolymyxins vActive only against gram-negative rods, particularly P.aeruginosavMechanism:increase permeability of cell membranevMainly used in P.aeruginosa infection when ot
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經權益所有人同意不得將文件中的內容挪作商業或盈利用途。
- 5. 人人文庫網僅提供信息存儲空間,僅對用戶上傳內容的表現方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
- 6. 下載文件中如有侵權或不適當內容,請與我們聯系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 電池行業發展趨勢與挑戰考核試卷
- 2025年新能源環衛裝備項目發展計劃
- 數字智慧方案5464丨全場景智慧工地整體解決方案
- 六年級下數學課件-分數與最小公倍數-蘇教
- 《清華大學高效管理策略》課件
- 《初中英語教師教學經驗分享課件》
- 《農業機械安全監管培訓》課件
- 我很重要獲獎課件
- 成都短視頻代運營公司
- 2025年超細粉碎設備(氣流磨)項目建議書
- 人教版(2019)選擇性必修第三冊Unit 4 Adversity and Courage 單詞講解課件
- 掛名法定負責人免責協議
- 2024-2025年全國初中化學競賽試卷及答案
- 2024年山東濟南先行投資有限責任公司招聘筆試參考題庫含答案解析
- 企業的經營指標分析報告
- 故事繪本表演游戲-:狐貍和兔子
- 教師技能大賽領導講話稿
- 遺囑繼承法律知識講座
- 腸系膜上動脈壓迫綜合征演示稿件
- 四年級上冊語文園地七教學反思
- 企業員工法律意識培訓課件
評論
0/150
提交評論